New Key Statistics Module, Z-Score and F-Score
XCNQ:DOSE Key Ratios
| Market Cap C$ M | 28.76 |
| Enterprise Value C$ M | 31.30 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | -- |
| Price/Sales | 21.82 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) C$ M | 1.00 |
| EPS (TTM) C$ | -0.04 |
| Beneish M-Score | 0 |
| 10-y EBITDA Growth Rate % | 13.10 |
| 5-y EBITDA Growth Rate % | 27.10 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -7.05 |
| EV-to-EBITDA | -7.92 |
| PEG | -- |
| Shares Outstanding M | 127.82 |
| Net Margin (%) | -401.86 |
| Operating Margin % | -288.45 |
| Pre-tax Margin (%) | -401.86 |
| Quick Ratio | 0.15 |
| Current Ratio | 0.21 |
| ROA % (ttm) | -283.60 |
| ROE % (ttm) | -- |
| ROIC % (ttm) | -214.89 |
| Dividend Yield % | -- |
| Altman Z-Score | -40.04 |
XCNQ:DOSE Number of Guru Trades
XCNQ:DOSE Volume of Guru Trades
Gurus Latest Trades with XCNQ:DOSE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
XCNQ:DOSE is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Rapid Dose Therapeutics Corp Insider Transactions
No Available Data
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers